Free Cash Flow per Share: A measure of financial performance calculated as operating cash flow minus capital expenditures, expressed on a per share basis. Calculated as: Free Cash Flow / Weighted Average Shares Outstanding (Diluted)
Silexion Therapeutics Corp (SLXN) had Free Cash Flow per Share of $-1.13 for the most recently reported fiscal quarter, ending 2026-03-31.
| Income Statement Financials | |
-- |
|
$-2.73M |
|
-- |
|
-- |
|
$2.75M |
|
$-2.75M |
|
$0.02M |
|
$-2.73M |
|
$-2.73M |
|
$-2.73M |
|
$-2.73M |
|
$-2.73M |
|
$-2.73M |
|
$-2.75M |
|
$-2.75M |
|
3.23M |
|
3.23M |
|
$-0.85 |
|
$-0.85 |
|
| Balance Sheet Financials | |
$4.07M |
|
$0.02M |
|
$0.54M |
|
$4.60M |
|
$4.06M |
|
-- |
|
$0.25M |
|
$4.31M |
|
$0.29M |
|
$0.29M |
|
$0.29M |
|
3.40M |
|
| Cash Flow Statement Financials | |
$-3.65M |
|
$0.00M |
|
$0.08M |
|
$6.08M |
|
$2.50M |
|
$-3.58M |
|
$0.34M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
1.00 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-3.65M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-939.16% |
|
-939.17% |
|
-59.39% |
|
-939.18% |
|
$0.09 |
|
|
Free Cash Flow per Share |
$-1.13 |
$-1.13 |
|